Of the 9285 statin initiators, 12% discontinued treatment within the first year.
High-patient co-payment was an independent risk factor for the discontinuation.
The only significant difference between genders was observed for risky alcohol use.
Risky alcohol use predicted discontinuation of treatment in women but not in men.